| Autor: |
Imholz, B., Imbach, P., Baumgartner, C., Berchtold, W., Gaedicke, G., Gugler, E., Hirt, A., Hitzig, W., Mueller-Eckhardt, C., Wagner, H. |
| Zdroj: |
Blut: Zeitschrift für die Gesamte Blutforschung; 1988, Vol. 56 Issue 2, p63-68, 6p |
| Abstrakt: |
In a prospective multicenter study 42 thrombocytopenic (<30×10 platelets/l) children with chronic idiopathic thrombocytopenic purpura (ITP) or with acute ITP, dependent on or refractory to corticosteroids, were given 0.4 g i.v. IgG/kg body weight/day on 5 consecutive days and thereafter once a week if the platelet count fell to <20×10/l or if the patient bled. After the initial 5 days of i.v. IgG the platelets rose within a mean of 7-8 days to >30×10/l in all and to >150×10/l in 33 of 42 patients (79%). After a mean observation time of 26.6 months 26 of 42 patients (62%) showed a satisfactory long-term effect, i.e. no need for treatment for at least 6 months without bleeding and with no platelet counts below 20×10/l. No difference in response rate was found between children with chronic and those with previously treated acute ITP. These results indicate that i.v. IgG could be used to control emergency situations, e.g. to stop bleeding or to prepare a patient for surgery. I.v. IgG also represents a good alternative to treatment modalities, such as splenectomy and/or the administration of cytostatic immunosuppressants with potentially serious side effects. In addition to the expected transient rise in serum IgG levels, i.v. IgG induced a more prolonged elevation of serum IgM. Platelet associated IgG, elevated before therapy, was correlated with the clinical long-term outcome. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
